{"Name":"Tosh Scheps","Level":"律师","ExceptionLanguage":"","PracticesPreviewOverride":"","ExtensionceAttorneyExperience":"

Recent examples of Tosh’s work include advising:

ADVANZ PHARMA, a Nordic Capital portfolio company, in connection with the issuance of €917 million (equivalent) in new euro- and pound sterling-denominated senior secured notes and the borrowing of a €165 million term loan B facility.

","ExtensionceAttorneyProBono":"","MembershipsAndAffiliations":"","CredentialsOverride":"","AdmissionsOverride":"","MobileExperienceHeader":"代理事宜","MobileExperienceNext":"代理事宜","PublicationLabel":"出版专著","EventLabel":"活动","NewsLabel":"新闻","NewsletterLabel":"Newsletters","StoryLabel":"企业故事","RichTextAreasModule":{"RichTextAreas":[{"Title":"","Overview":"","OverviewExpanded":"

TOSH SCHEPS advises both issuers and underwriters on international corporate finance transactions and U.S. securities regulation, with a particular focus on high-yield debt capital markets transactions and complex cross-border financing arrangements.

*Admitted to practice in California. Not admitted to practice in England and Wales.

","OverviewReadMoreLabel":"More","OverviewViewLessLabel":"Less"}],"CssClass":null,"FolderTemplateID":null,"SiteImproveReadMoreDataAttributes":""},"RelatedArticles":{"ResultCount":1,"HasMoreResults":false,"GridData":[{"ID":"4ee11c61-f254-41a2-b02f-27416ef08519","ContentType":"公告","DisplayDate":"April 10, 2025","Title":"Sidley Advises ADVANZ PHARMA on €1.08 Billion (Equivalent) Refinancing","ShortTitle":"","Summary":"","Source":"","Location":null,"Tags":null,"NavigateLink":{"ViewUrls":[{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"itlang","CurrentViewID":null,"Name":null,"Url":"/it/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"itlang","CurrentViewID":null,"Name":null,"Url":"/it/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"kolang","CurrentViewID":null,"Name":null,"Url":"/ko/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"kolang","CurrentViewID":null,"Name":null,"Url":"/ko/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"pllang","CurrentViewID":null,"Name":null,"Url":"/pl/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"pllang","CurrentViewID":null,"Name":null,"Url":"/pl/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"hilang","CurrentViewID":null,"Name":null,"Url":"/hi/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"hilang","CurrentViewID":null,"Name":null,"Url":"/hi/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"jalang","CurrentViewID":null,"Name":null,"Url":"/ja/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"jalang","CurrentViewID":null,"Name":null,"Url":"/ja/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"bglang","CurrentViewID":null,"Name":null,"Url":"/bg/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"bglang","CurrentViewID":null,"Name":null,"Url":"/bg/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"ptlang","CurrentViewID":null,"Name":null,"Url":"/pt/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"ptlang","CurrentViewID":null,"Name":null,"Url":"/pt/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"idlang","CurrentViewID":null,"Name":null,"Url":"/id/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"idlang","CurrentViewID":null,"Name":null,"Url":"/id/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"zhlang","CurrentViewID":null,"Name":null,"Url":"/zh-hans/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"zhlang","CurrentViewID":null,"Name":null,"Url":"/zh-hans/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"delang","CurrentViewID":null,"Name":null,"Url":"/de/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"delang","CurrentViewID":null,"Name":null,"Url":"/de/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"nllang","CurrentViewID":null,"Name":null,"Url":"/nl-nl/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"nllang","CurrentViewID":null,"Name":null,"Url":"/nl-nl/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"frlang","CurrentViewID":null,"Name":null,"Url":"/fr/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"frlang","CurrentViewID":null,"Name":null,"Url":"/fr/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"rulang","CurrentViewID":null,"Name":null,"Url":"/ru/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"rulang","CurrentViewID":null,"Name":null,"Url":"/ru/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"eslang","CurrentViewID":null,"Name":null,"Url":"/es/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"eslang","CurrentViewID":null,"Name":null,"Url":"/es/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"enlang","CurrentViewID":null,"Name":null,"Url":"/en/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"enlang","CurrentViewID":null,"Name":null,"Url":"/en/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"}],"Url":"/en/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing","Title":"Sidley Advises ADVANZ PHARMA on €1.08 Billion (Equivalent) Refinancing","Target":"_self","CssClass":"","Language":"","IsActive":false,"IsExternal":false,"Children":null},"TemplateID":"c7ca4050-a9f3-4e7c-a3cc-0277d1cfb7eb"}],"UpcomingEvents":[],"SearchFilters":{"CurrentViewID":"957999b3-455b-43de-a2cb-f8856c9b68cf","Skip":0,"Take":4,"InitialPageSize":4,"ReloadFilters":false,"SeparateUpcomingEvents":false,"CurrentDayEventsOnly":false,"UpcomingEventsOnly":false,"IsBioOnly":true,"DateFrom":null,"DateTo":null,"KeywordFilter":"","PinnedItems":"","ExcludedPinnedItems":"","UsePinnedItems":true,"SortField":0,"PracticeFilters":[],"IndustryFilters":[],"TypeFilters":[],"MediaFilters":null,"EventTypeFilters":[],"ArticleTypeFilters":[{"RichTextContent":"","PinnedItems":"","DisplaySearchResultListing":true,"IsResources":false,"IsMedia":false,"ID":"dbb4c9d1-b36c-4588-b283-e8407fc49c7d","Name":"新闻","Title":null,"Url":"","IsSelected":true,"IsEnabled":true,"Filter":[]}],"DateFilters":[],"TopicFilters":[],"BlogFilters":[],"OtherFilters":[{"ID":"cd1ac5f8-3db7-4fc3-9b85-28341986cabe","Name":null,"Title":null,"Url":null,"IsSelected":true,"IsEnabled":true,"Filter":[]}],"ProBonoFilters":[],"SingleResultLabel":null,"MultipleResultLabel":null},"ShowSection":true,"Query":null,"MediaViewModel":null,"FeaturedHeader":null,"FeaturedSubHeader":null},"PublicationOverride":null,"EventOverride":null,"RepresentativeMattersDefaultClass":null,"ProBonoDefaultClass":null,"MembershipDefaultClass":null,"DisclaimerNotAdmittedToPractice":"*Admitted to practice in California. Not admitted to practice in England and Wales.","HasCallToActions":false,"HasAdditionalDetail":true,"IsOneTab":true,"OneTabCss":"one-tab"}

执业资格及证书

学历和教育